Dutasteride/tamsulosin: In benign prostatic hyperplasia

Drugs and Aging

Volumn 29, Issue 5, 2012, Pages 405-419

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Benign prostatic hyperplasia; Dutasteridetamsulosin; Elderly

Indexed keywords

DUTASTERIDE; DUTASTERIDE PLUS TAMSULOSIN; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ARTICLE; BREAST TENDERNESS; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO DISORDER; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROGRADE EJACULATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AZASTEROIDS; DRUG COMBINATIONS; HUMANS; MALE; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 84860574864     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11208920-000000000-00000     Document Type: Article

References (48)

1. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH) [online]. Available from URL: http://www.auanet.org/content/clinical-practice-guidelines/ clinical-guidelines.cfm?sub=bph [Accessed 2011 Nov 21]
2. Djavan B, Handl MJ, Dianat S. Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Pharmacother 2010; 11 (15): 2535-47
3. Oelke M, Bachmann A, Descazeaud A, et al. The treatmtent of non-neurogenic male LUTS [online]. Available from URL: http://www.uroweb.org/ gls/pdf/12-Male-LUTS.pdf [Accessed 2011 Nov 21]
4. National Institute for Health and Clinical Excellence. Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. NICE clinical guideline 97 [online]. Available from URL: http://www.nice.org.uk/ nicemedia/ live/12984/48557/48557.pdf [Accessed 2011 Dec 8]
5. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate. Clin Ther 2007 Jan; 29 (1): 17-25
6. Gravas S, Oelke M. Current status of 5a-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010 Feb; 28 (1): 9-15
7. Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009; 4: 251-8
8. GlaxoSmithKline. Jalyn (dutasteride and tamsulosin hydrochloride) capsules: US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/ us-jalyn.pdf [Accessed 2011 Nov 17]
9. Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adhere 2011; 5: 483-90
10. Naslund M, Eaddy MT, Hogue SL, et al. Impact of delaying 5-alpha reductase inhibitor therapy in men on alphablocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin 2009 Nov; 25 (11): 2663-9
11. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011 Mar; 107 (6): 876-80
12. Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders.Drugs 2008; 68 (4): 463-85
13. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin EndocrinolMetab 2004May; 89 (5): 2179-84
14. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 Apr; 63 (4): 709-15
15. Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10 (2): 149-54
16. Rittmaster RS, Norman RW, Thomas LN, et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996 Feb; 81 (2): 814-9
17. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57 (1): 123-31
18. GlaxoSmithKline UK. Combodart (dutasteride/tamsulosin) 0.5 mg/0.4 mg hard capsule: UK summary of product characteristics [online]. Available from URL: http://www. medicines.org.uk/EMC/medicine/22943/SPC/Combodart+0.5+ mg+++0.4+mg+hard+capsules/ [Accessed 2012 Apr 26]
19. Yamada S, Kato Y, Okura T, et al. Prediction of a1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull 2007 Jul; 30 (7): 1237-41
20. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62 (1): 135-67
21. Matsushima H, Kamimura H, Soeishi Y, et al. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998 Mar; 26 (3): 240-5
22. van Hoogdalem EJ, Soeishi Y, Matsushima H, et al. Disposition of the selective a1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997 Oct; 86 (10): 1156-61
23. Kamimura H, Oishi S, Matsushima H, et al. Identification of cytochrome P450 isozymes involved in metabolism of the a1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998 Oct; 28 (10): 909-22
24. Soeishi Y, Matsushima H, Watanabe T, et al. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 1996 Jun; 26 (6): 637-45
25. Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998 Jul; 54 (4): 367-73
26. Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res 2001 Sep; 62 (9): 603-21
27. Clark R, Haberer L. The dual 5a-reductase inhibitor dutasteride is well tolerated and has no effect on the pharmacokinetic profiles of tamsulosin or terazosin when used in combination in healthy male volunteers [abstract no. 840]. Eur Urol Suppl 2005 Mar; 4 (3): 212
28. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 Feb; 179 (2): 616-21
29. Siami P, Roehrborn CG, Barkin J, et al. Combination therapy with dutasteride and tamsulosin in men with moderateto- severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28 (6): 770-9
30. Becher E, Roehrborn CG, Siami P, et al. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 2009; 12 (4): 369-74
31. Montorsi F, Roehrborn C, Garcia-Penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int 2011; 107 (9): 1426-31
32. Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55 (2): 461-71
33. Chung B-H, Roehrborn CG, Siami P, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis 2009; 12 (2): 152-9
34. Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 2011; 107 (6): 946-54
35. Haillot O, Fraga A, Maciukiewicz P, et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis 2011 Dec; 14 (4): 302-6
36. Tubaro A, Roehrborn CG, Barkin J, et al. Clinical outcomes after combination therapy with dutasteride and tamsulosin in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4 year results from the randomized, doubleblind, CombAT trial [poster]. 25th Congress of the European Association of Urology; 2010 Apr 16-20; Barcelona
37. Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009; 103 (7): 919-26
38. Montorsi F, Henkel T, Geboers A, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010 Jul; 64 (8): 1042-51
39. Bjerklund Johansen TE, Baker TM, Black LK. Costeffectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int 2012 Mar; 109 (5): 731-8
40. Antoñanzas F, Brenes F, Molero JM, et al. Costeffectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain. Actas Urol Esp 2011; 35 (2): 65-71
41. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349 (25): 2387-98
42. Montlleó Gonzá lez M, Geiges G, Cicalese V, et al. Combination therapy with dutasteride plus tamsulosin reduces medical resource utilisation in men with benign prostatichyperplasia: 4-year data from the CombAT study [abstract plus poster]. 25th Congress of the European Association of Urology; 2010 Apr 16-20; Barcelona
43. Roehrborn CG, Andriole GL, Wilson TH, et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011; 59 (2): 244-9
44. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. New Engl J Med 2010 Apr 1; 362 (13): 1192-202
45. Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011 Jan; 185 (1): 126-31
46. Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2012 Apr; 109 (8): 1162-9
47. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005 Sep; 174 (3): 877-81
48. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 Jul 17; 349 (3): 215-24